跳至主要内容
临床试验/NCT04255589
NCT04255589已完成3 期

A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis

Chong Kun Dang Pharmaceutical17 个研究点 分布在 1 个国家目标入组 242 人开始时间: 2020年1月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
242
试验地点
17
主要终点
Improvement rate of gastric erosion

研究概览

简要总结

To Evaluate the Efficacy and Safety of CKD-495

详细描述

A phase 3, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female subjects aged ≥ 19
  • Acute or Chronic gastritis patients who have more than 1 erosion on endoscopy within 7days prior to the use of the Investigator's Product taken date
  • Patients who have more than 1 subjective symptom

排除标准

  • Patients with peptic ulcer, gastroesophageal reflux disease, malignant tumor in the digestive system or coagulation disorder, or taking antithrombotic medicine
  • Patients who have been taken any gastritis medicine that could affect the treatment: H2 receptor antagonist, PPI(Proton Pump Inhibitor), antacid, improvement of movement in digestive system, Prostaglandin, and protective agent for gastritis
  • Patients who have to take medicine that could cause gastritis

研究组 & 干预措施

Experimental Group

Experimental

Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)

干预措施: CKD-495 75mg (Drug)

Experimental Group

Experimental

Patients assigned to this group are treated with one CKD-495 75mg Tab.,and one Placebo Tab.(Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab)

干预措施: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg (Drug)

Active comparator Group

Active Comparator

Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)

干预措施: Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg (Drug)

Active comparator Group

Active Comparator

Patients assigned to this group are treated with one Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and one Placebo Tab.(Placebo of the CKD-495 75mg)

干预措施: Placebo of the CKD-495 75mg (Drug)

结局指标

主要结局

Improvement rate of gastric erosion

时间窗: 14days after drug administrations

50% change on erosive grade

次要结局

  • cure rate of gastric erosion(14days after drug administrations)
  • Improvement rate of gastric edema(14days after drug administrations)
  • Improvement rate of symptoms(14days after drug administrations)
  • Improvement rate of gastric erythema(14days after drug administrations)
  • Improvement rate of gastric hemorrhage(14days after drug administrations)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (17)

Loading locations...

相似试验